From educating her colleagues to sharing stories of hope & words of encouragement with her patients, pediatric rheumatology resident Adaobi Ugochukwu draws on her own experience with lupus to ensure that patients receive empathetic, compassionate care.
Learn how to identify & combat age-based discrimination for improved communication & better patient outcomes.
Pediatric rheumatologic diseases are characterized by high rates of anxiety & depression known to impact health-related outcomes. CARRA and the ACR developed guidance statements to assess & manage mental health concerns for youths in pediatric rheumatology practice.
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.
A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue & pain than patients who received placebo.